Donor-Derived Cell-Free DNA and Active Rejection in Renal Allografts

Overview

Journal Indian J Nephrol

Specialty Nephrology

Date 2023 Oct 2

PMID 37781552

Authors

Edwin Fernando

Harshavardhan Trichy Sanathkumar

Aravind Ramanathan

N D Srinivasaprasad

K Thirumalvalavan

Poongodi Annadurai

S Sujith

Affiliations

Soon will be listed here.

Abstract

Background: Renal allograft rejection contributes to significant morbidity and graft loss. In this setting, early detection of rejection is of paramount importance, which currently relies on histopathology. A reliable non-invasive marker to predict rejection would make surveillance and decision-making easier. Donor-derived cell-free DNA (dd-Cf-DNA) has recently been reported as an emerging tool to predict rejection noninvasively. The utility of cell-free DNA in clinical practice has so far not been studied in an Indian setting. As it offers direct clinical application, we have chosen to investigate this biomarker as a tool to predict rejection.

Materials And Methods: A pilot study with convenient sample size was designed, as this is the first of its kind study so far reported from India. Patients being evaluated with a graft biopsy for graft dysfunction were included. Patients with stable graft function, defined as creatinine within 10% of their best creatinine and no proteinuria for the preceding 12 months, were also included. Ten milliliters of whole blood from each of the recipients was collected in DNA isolation tubes. Two milliliters of donor blood was also obtained in ethylenediaminetetraacetic acid (EDTA) tubes. All recipients also provided a buccal swab. Total cell-free DNA was extracted from 2 ml of recipient plasma using circulating DNA isolation kit. Upon identification of the donor-specific DNA marker for each of the patients from the paired donor sample, presence of the cell-free DNA fraction in the recipient's plasma was detected and quantified. Renal biopsy reports and clinical details were also recorded. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were analyzed. Receiver operating characteristic (ROC) curve analysis was also performed.

Results: A total of 31 patients were recruited. Twenty patients underwent graft biopsies for graft dysfunction, of which 12 patients had features of active rejection and eight had nonrejection causes of graft dysfunction. Eleven patients with stable graft were included in the study. In our study, dd-Cf-DNA performed best in predicting antibody-mediated rejection (ABMR) and higher grades of T-cell-mediated rejection (TCMR) (1B). It did not detect TCMR 1A accurately. It serves as a good marker to rule out rejection. It gave a NPV of 100% for TCMR 1B or ABMR, 100% for ABMR alone, and 81% for any rejection. dd-Cf-DNA percentages outperform absolute concentrations in their discriminatory ability.

Conclusion: We have demonstrated the diagnostic accuracy of dd-Cf-DNA in predicting active rejection of the renal allograft. It performs well in ABMR and higher grades of TCMR. This is the first of its kind study reported from India, to the best of our knowledge. This tool serves as a good rule out test for ABMR and higher grades of TCMR. It performs poorly in TCMR 1A.

References

Nankivell B, Chapman J . The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant. 2006; 6(9):2006-12. DOI: 10.1111/j.1600-6143.2006.01436.x. View

Bromberg J, Brennan D, Poggio E, Bunnapradist S, Langone A, Sood P . Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications. J Appl Lab Med. 2021; 2(3):309-321. DOI: 10.1373/jalm.2016.022731. View

Sigdel T, Archila F, Constantin T, Prins S, Liberto J, Damm I . Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR. J Clin Med. 2018; 8(1). PMC: 6352163. DOI: 10.3390/jcm8010019. View

Jevnikar A, Mannon R . Late kidney allograft loss: what we know about it, and what we can do about it. Clin J Am Soc Nephrol. 2008; 3 Suppl 2:S56-67. PMC: 3152273. DOI: 10.2215/CJN.03040707. View

Hurkmans D, Verhoeven J, de Leur K, Boer K, Joosse A, Baan C . Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment. J Immunother Cancer. 2019; 7(1):182. PMC: 6626432. DOI: 10.1186/s40425-019-0653-6. View

Beck J, Oellerich M, Schulz U, Schauerte V, Reinhard L, Fuchs U . Donor-Derived Cell-Free DNA Is a Novel Universal Biomarker for Allograft Rejection in Solid Organ Transplantation. Transplant Proc. 2015; 47(8):2400-3. DOI: 10.1016/j.transproceed.2015.08.035. View

Schutz E, Fischer A, Beck J, Harden M, Koch M, Wuensch T . Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study. PLoS Med. 2017; 14(4):e1002286. PMC: 5404754. DOI: 10.1371/journal.pmed.1002286. View

Gielis E, Ledeganck K, DE Winter B, Del Favero J, Bosmans J, Claas F . Cell-Free DNA: An Upcoming Biomarker in Transplantation. Am J Transplant. 2015; 15(10):2541-51. DOI: 10.1111/ajt.13387. View

Seeto R, Fleming J, Dholakia S, Dale B . Understanding and using AlloSure donor derived cell-free DNA. Biophys Rev. 2020; 12(4):917-924. PMC: 7429580. DOI: 10.1007/s12551-020-00713-5. View

10.

Martuszewski A, Paluszkiewicz P, Krol M, Banasik M, Kepinska M . Donor-Derived Cell-Free DNA in Kidney Transplantation as a Potential Rejection Biomarker: A Systematic Literature Review. J Clin Med. 2021; 10(2). PMC: 7827757. DOI: 10.3390/jcm10020193. View

11.

Gielis E, Beirnaert C, Dendooven A, Meysman P, Laukens K, De Schrijver J . Plasma donor-derived cell-free DNA kinetics after kidney transplantation using a single tube multiplex PCR assay. PLoS One. 2018; 13(12):e0208207. PMC: 6283554. DOI: 10.1371/journal.pone.0208207. View

12.

Jordan S, Bunnapradist S, Bromberg J, Langone A, Hiller D, Yee J . Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients. Transplant Direct. 2018; 4(9):e379. PMC: 6133406. DOI: 10.1097/TXD.0000000000000821. View

13.

Gielis E, Ledeganck K, Dendooven A, Meysman P, Beirnaert C, Laukens K . The use of plasma donor-derived, cell-free DNA to monitor acute rejection after kidney transplantation. Nephrol Dial Transplant. 2019; 35(4):714-721. DOI: 10.1093/ndt/gfz091. View

14.

Josephson M . Monitoring and managing graft health in the kidney transplant recipient. Clin J Am Soc Nephrol. 2011; 6(7):1774-80. DOI: 10.2215/CJN.01230211. View

15.

Bloom R, Bromberg J, Poggio E, Bunnapradist S, Langone A, Sood P . Cell-Free DNA and Active Rejection in Kidney Allografts. J Am Soc Nephrol. 2017; 28(7):2221-2232. PMC: 5491290. DOI: 10.1681/ASN.2016091034. View

16.

Bansal S, Fleming T, Mohanakumar T . The detection of donor-derived cell-free DNA may serve as a biomarker for the early detection of chronic lung allograft dysfunction. EBioMedicine. 2019; 40:13-14. PMC: 6413678. DOI: 10.1016/j.ebiom.2019.01.044. View